Skip to main content
|
  1. Home
  2. Clinical Trials
  3. Inavo122/WO44263

Inavolisib in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

Short Title: Inavo122/WO44263


Enrollment Status: Recruiting

NCT #: NCT05894239

Specialty Area: Oncology

Condition Studied: Locally Advanced or Metastatic Breast Cancer

Age Groups: Adult; Older Adult

Phase: II/III


Study Information

Summary / Purpose

To find out if adding inavolisib to the usual maintenance treatment (Phesgo) helps people with HER2-positive, PIK3CA-mutated advanced breast cancer live longer, feel better, and delay cancer progression.

Study Type: Interventional
Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:
  • Adults 18+ years of age
  • Diagnosed with HER2-positive and PIK3CA mutated breast cancer that has spread beyond the breast (locally advanced or metastatic)
  • Already completed first round of treatment (induction therapy)
  • No active autoimmune disease

What's Involved

Participation in the study will include:
  • Intravenous (IV) infusion of the study medication
  • Treatment with Phesgo (pertuzumab, trastuzumab, and rHuPH20) with or without inavolisib
  • CT/MRI scans to monitor response to treatment
  • Blood and urine tests to monitor your health and treatment effects
  • Electrocardiogram (ECG) to monitor heart function
  • Questionnaires

Principal Investigator

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Complete Study Details: https://clinicaltrials.gov/study/NCT05894239

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.

ER Wait Times

How are wait times calculated?

Our estimated ER wait times reflect the average time from check-in to being seen by a medical professional during triage, where patients are prioritized based on the severity of their condition.

Health & Wellness eNews
Sign Up